Browsing by Author "Karhan, O."

Now showing 1 - 4 of 4

Efficacy of Gemcitabine Plus Nab-Paclitaxel in Second-Line Treatment of Metastatic Pancreatic Cancer
(Elsevier, 2024) Sezgin, Y.; Karhan, O.; Urakci, Z.; Mecidova, N.; Araz, M.; Sakin, A.; Ergun, Y.
Efficacy of Gemcitabine Plus Nab-Paclitaxel in Second-Line Treatment of Metastatic Pancreatic Cancer
(Nature Research, 2025) Sezgin, Y.; Karhan, O.; Aldemir, M.N.; Ürün, M.; Erçek, B.M.; Urakcı, Z.; Ergün, Y.
Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a second-line treatment. This study aims to examine the efficacy of gemcitabine plus nab-paclitaxel in second-line therapy. In this retrospective study, a total of 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), treatment efficacy based on ECOG performance status (PS), and tumor marker (CEA, CA 19 − 9) levels. In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 5.6 to 7.1), and the median OS was 8.6 months (95% CI, 7.3 to 10.0). Median PFS was 6.6 months in patients with normal CEA levels compared to 4.4 months in patients with high CEA levels (P = 0.01). Median PFS was 6 months in patients with ECOG PS 0–1 compared to 3.8 months in patients with PS 2 (P < 0.01). This study demonstrates the contribution of gemcitabine plus nab-paclitaxel in both OS and PFS in second-line treatment of metastatic pancreatic cancer. It was found to be a good option especially for young patients with good ECOG PS. © The Author(s) 2025.
Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient With Larnyngeal Cancer
(Wolters Kluwer Medknow Publications, 2024) Karhan, O.; Sezgin, Y.; Ileri, S.; Tunc, S.
Mesenteric panniculitis is rare, usually idiopathic, caused by inflammation of the fatty tissue of the mesentery, especially in the small intestine. The relation between cancer and mesenteric panniculitis is unclear. In some studies, mesenteric pannicullitis precedes cancer diagnosis; on the other hand, some studies suggest no correlations. Immunotherapeutics have a wide range of side effects; virtually, every system and organ in the body can be affected. Herein, we presented a rare case of mesenteric panniculitis in a patient with larnyngeal cancer as a side effect of nivolumab treatment. The patient was presented with nausea and vomiting and diagnosed with intravenous contrast-enhanced computed tomography and fully recovered with corticosteroid treatment. The case report highlights the importance of noticing rarely seen side effects of immunotherapy which can be treated easily with immunosuppressive agents.
The Prediction of Overall Survival With The Use of The Sarculator in Operated Soft Tissue Sarcoma of The Extremities: Monocentre Experience
(Yuzuncu Yil Universitesi Tip Fakultesi, 2023) Sezgin, Y.; Karhan, O.
Soft tissue sarcomas are rare malignancies with poor prognosis and more than 100 histologic subtypes. Due to their poor prognosis, accurate prognosis cannot be made by the staging system alone. Therefore, normograms have been developed for sarcoma patients. In this study, it was aimed to investigate the real-life data of prognosis prediction of sarculator normogram. Retrospective observational research was used in our study and the records of 146 patients were reviewed. The study included 50 patients who met the study criteria. The prognostic factors in sarcoma patients were analyzed in the study. Tumor size, tumor grade, age, and histologic subtype of the tumor were examined. In addition, all patients were graded using the sarcoma normogram and divided into percentile groups. The study's patient population had a median age of 47 years. 37 months was the median overall survival time. Patients with tumor grade 3 showed a statistically lower overall survival than those with grade 1 according to univariate analysis. Among patients divided into three groups according to Sarculator scoring, the high-risk group had a statistically significant difference of 23 months, the intermediate-risk group of 39 months, and the good-risk group of 93 months. Increased tumor size and grade were statistically significantly associated with poor survival, which was consistent with the literature. Statistically significant 5-10 year survival data were obtained in patients divided into 3 groups and compared with sarcolator. Thus, the accuracy of the Sarcolator was confirmed with real-world data. © 2023, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.